跳至主要内容
临床试验/NCT06673134
NCT06673134进行中(未招募)不适用

Prospective Registry Study and Clinical Observation of Children With Crohn's Disease

Tongji Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年12月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
100
试验地点
1
主要终点
To evaluate the clinical manifestations, treatment options, and clinical outcomes of Crohn's disease in children in real-world Settings

研究概览

简要总结

To evaluate the clinical manifestations, treatment options, and improved clinical outcomeof children with Crohn's disease in real-world Settings: (1) analysis of clinical manifestations; (2) probability of using the same treatment options; (3) Clinical outcome;

详细描述

This study will aim to enroll approximately 100 patients with Crohn Disease (CD). All patients who have CD will be evaluated at the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Patients who are eligible for the study will be identified during these regularly scheduled clinic visits. Patients and guardians who express interest will be set up for a meeting with a clinical research coordinator who will go over the study in detail and will obtain informed consent. Before the therapeutic intervention,stool samples will be checked for ova and parasites, C. difficile toxin and fecal calprotectin (FCP). Serum tests will include erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Anti-nuclear antibodies (ANA), complete blood cell count, HIV, screening for Hepatitis A, B, C (hep A IgM, hep B surface antigen and antibody, Hep C antibody), and creatinine. Fecal tests included 16S rDNA flora detection and metabolite detection. Patients with CD will undergo colonoscopy, which is considered part of standard of care for patients with ongoing inflammation and is not considered a study procedure.

Dynamic monitoring follow-up up to 102 weeks, dynamic assessment of relevant indicators, such as ESR, CRP, FCP and endoscopy, etc. This study is an observational study, without intervention in the treatment of patients. Patients will accept the treatment plan formulated by the attending physician. Treatment options include: enteral nutrition (EEN/ PEN, reason, route of administration, dose, course of treatment); glucocorticoids (reason, route of administration, dose, course of treatment); immunosuppressants (reason, route of administration, dose, course of treatment); biologics (including domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd)) (dose, duration, effectiveness, safety, and economy); fecal microbiota transplantation (cause, transplantation routes, capsule fecal transplants, dose, course of treatment); the medical costs and resource consumption of the treatment of Crohn's disease in children. The difference of efficacy of the above treatment schemes was recorded, the treatment outcome was compared, and the transformation of treatment schemes was discussed. Researchers and patients will truthfully register the corresponding data generated by clinical practice from the doctors and patients respectively, collect the laboratory examination and evaluation data of doctors during the visit, and combine the hospital visit and electronic information system. Statistical analysis was performed after follow-up.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
1 Month 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children under 17 years old;
  • Children with a definite diagnosis of Crohn's disease;
  • Patients and their guardians must sign informed consent;

排除标准

  • Other conditions deemed inappropriate by the doctor to participate in the study;

研究组 & 干预措施

Glucocorticoid group

Glucocorticoid therapy

干预措施: biological agents (Drug)

Immunosuppressive group

Immunosuppressive therapy

干预措施: biological agents (Drug)

Glucocorticoid group

Glucocorticoid therapy

干预措施: fecal microbiota transplantation (Other)

Immunosuppressive group

Immunosuppressive therapy

干预措施: enteral nutrition (Drug)

enteral nutrition group

enteral nutrition therapy, including exclusive enteral nutrition and Partial enteral nutrition

干预措施: Immunotherapy (Drug)

enteral nutrition group

enteral nutrition therapy, including exclusive enteral nutrition and Partial enteral nutrition

干预措施: biological agents (Drug)

enteral nutrition group

enteral nutrition therapy, including exclusive enteral nutrition and Partial enteral nutrition

干预措施: Glucocorticoids (Drug)

enteral nutrition group

enteral nutrition therapy, including exclusive enteral nutrition and Partial enteral nutrition

干预措施: fecal microbiota transplantation (Other)

Glucocorticoid group

Glucocorticoid therapy

干预措施: enteral nutrition (Drug)

Immunosuppressive group

Immunosuppressive therapy

干预措施: fecal microbiota transplantation (Other)

Fecal Microbiota Transplantation group

Fecal Microbiota Transplantation therapy

干预措施: enteral nutrition (Drug)

Fecal Microbiota Transplantation group

Fecal Microbiota Transplantation therapy

干预措施: Immunotherapy (Drug)

Fecal Microbiota Transplantation group

Fecal Microbiota Transplantation therapy

干预措施: biological agents (Drug)

Fecal Microbiota Transplantation group

Fecal Microbiota Transplantation therapy

干预措施: Glucocorticoids (Drug)

Biologics group

Biologics therapy, Including various types of biological agents, as well as domestic biological agents (Taizhou Mabtech Pharmaceutical Co.,Ltd).

干预措施: enteral nutrition (Drug)

Biologics group

Biologics therapy, Including various types of biological agents, as well as domestic biological agents (Taizhou Mabtech Pharmaceutical Co.,Ltd).

干预措施: Immunotherapy (Drug)

Biologics group

Biologics therapy, Including various types of biological agents, as well as domestic biological agents (Taizhou Mabtech Pharmaceutical Co.,Ltd).

干预措施: Glucocorticoids (Drug)

Biologics group

Biologics therapy, Including various types of biological agents, as well as domestic biological agents (Taizhou Mabtech Pharmaceutical Co.,Ltd).

干预措施: fecal microbiota transplantation (Other)

结局指标

主要结局

To evaluate the clinical manifestations, treatment options, and clinical outcomes of Crohn's disease in children in real-world Settings

时间窗: 14 weeks

14 weeks clinical response rate.

次要结局

  • Clinical remission of different treatment regimens(14 and 54 weeks)
  • Clinical response of different treatment regimens(54 weeks)
  • Endoscopic response of different treatment regimens(14 and 54 weeks)
  • Mucosal healing of different treatment regimens(14 and 54 weeks)
  • C-reactive protein of different treatment regimens(14 and 54 weeks)
  • Erythrocyte sedimentation rate of different treatment regimens(14 and 54 weeks)
  • Fecal calprotectin of different treatment regimens(14 and 54 weeks)
  • Intestinal flora of different treatment regimens(14 and 54 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Biao Zou

Attending physician, pediatric department

Tongji Hospital

研究点 (1)

Loading locations...

相似试验

Prospective Cohort Establishment and Clinical... | 临床试验